MBX

MBX is a clinical-stage peptide company with no product revenue and a widening loss (-$87.0M in FY2025, the third straight year of deepening losses: -$32.6M → -$61.9M → -$87.0M). Returns on capital are deeply negative (ROE -23.6%) and operating cash flow ran -$79.9M, so this is a pre-commercial story valued entirely on pipeline. What separates MBX from a typical 'avoid' burn-the-cash biotech is the balance sheet and the de-risking of the lead asset. Liabilities are a trivial $15.9M against $369M of equity (liabilities/equity 0.04x), and current assets of $382M dwarf the -$80M annual burn — roughly four-plus years of runway even before any further raise, which directly softens the 10-K's own going-concern-flavored warning that it 'will need substantial additional funding.'

The pipeline is genuinely advanced for the stage. Lead candidate canvuparatide (MBX 2109) for chronic hypoparathyroidism hit its primary endpoint in a 64-patient Phase 2 with a statistically significant Week-12 responder rate, positive six-month open-label data, no treatment-related serious adverse events and zero discontinuations — a clean profile on a clinically validated PTH target with an established regulatory path. The End-of-Phase-2 FDA meeting is done and Phase 3 is slated for Q3 2026, with one-year OLE data due Q2 2026. Behind it sits an obesity shot-on-goal, MBX 4291, a once-monthly GLP-1/GIP co-agonist, but it is only in Phase 1 with 12-week MAD data not expected until Q4 2026 — optionality, not yet evidence.